Maximus review

Maximus’s current brand-pricing guide lists Foundayo from $299.99 monthly and Wegovy tablets from $349.99 at the entry strengths. It separates the discounted first month from ongoing rates and lists higher-dose tiers. Those are cash program offers that include medication, clinical oversight and shipping, with no separate brand-access membership; required laboratory testing is additional. They are not manufacturer savings-card prices or guarantees that a starting-dose cost lasts through maintenance. The Foundayo guide and oral semaglutide guide explain the different approved products.

Brand injections have separate prices and formulations. The guide lists starting offers for Wegovy at $449.99 and Zepbound at $549.99, while some higher prescribed strengths cost more. Ozempic and Mounjaro are described as off-label for weight management in this program; that is distinct from an approval for that use. Confirm the actual prescribed product, device, dose tier and monthly total. Maximus says an upgrade is shown for confirmation when a prescription moves into a higher price tier. Insurance is not accepted for these plans. Pharmacy fulfillment and clinical suitability remain conditional despite the public price list.

The compounded pricing sources require reconciliation. The help center gives one-, four-, six- and twelve-month options, while the main weight-loss page presents different tirzepatide commitments and rates. Obtain the selected agreement in writing rather than treating either table as a universal offer. The help center explicitly describes monthly shipping with a 28-day supply; that does not establish a charge or shipment every 28 days. Twelve monthly supplies of 28 days are shorter than continuous full-year treatment. California semaglutide orders also have a per-shipment surcharge. Longer plans can have upfront payments and different shipment schedules; general savings-plan terms elsewhere describe monthly installments for a committed term. Confirm which terms govern your actual product, the amount paid now and the remaining obligation if treatment changes.

Clinical care includes medical-history review, baseline laboratory results and a refill questionnaire before renewal. Follow-up testing can be required, and overdue labs can prevent refill approval. The shipping guide says longer compounded plans may send 56 days of medication every two months, with prescription adjustments planned by the clinician before that shipment. It does not promise a new clinical check-in midway through every longer supply. Ask about contact between shipments, laboratory costs and what happens if the prescribed treatment becomes unsuitable. Cold-chain shipments are described on a Monday-through-Thursday schedule, with transit and delivery estimates after approval and pharmacy preparation. The portal is for nonurgent questions; it should not be treated as emergency monitoring.

The terms describe Maximus Medical Group Practices and possible additional affiliated practices, rather than guaranteeing one group for every offering. The help center identifies compounded pharmacy abbreviations EVR, FCC and VIOS according to state, and The Pharmacy Hub for brand medication. These are company sourcing disclosures, not independent license verification or proof of the pharmacy assigned to you. The current state guide excludes Alabama, Louisiana and Mississippi and warns that microdose availability can have additional limits. Cancellation and refund rules depend on the agreement and service: general fees are described as nonrefundable, while canceled company orders and a separate unused-lab subscription window have specified exceptions. Do not apply the laboratory refund window to a dispensed prescription. Confirm the renewal cutoff and remaining prepaid or installment commitment before relying on a dashboard cancellation. The pill lineup and billing checklist help compare these terms.